The safety of mycophenolate mofetil in pregnancy

Expert Opinion on Drug Safety

Volumn 7, Issue 3, 2008, Pages 219-222

  Pisoni, Cecilia N ^a   D'Cruz, David P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Connective tissue disease; Lupus; Mycophenolate mofetil; Pregnancy

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CONTRACEPTIVE AGENT; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

AUTOIMMUNE DISEASE; CLEFT LIP PALATE; CLEFT PALATE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; EXTERNAL EAR MALFORMATION; FACE MALFORMATION; FETUS DISEASE; FIRST TRIMESTER PREGNANCY; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PREGNANCY DISORDER; PREVALENCE; RHEUMATIC DISEASE; TERATOGENICITY; ADULT; ANIMAL; DRUG CONTRAINDICATION; FEMALE; FETOMATERNAL TRANSFUSION; ORGAN TRANSPLANTATION; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANIMALS; CRANIOFACIAL ABNORMALITIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MATERNAL-FETAL EXCHANGE; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 44949095328     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.3.219     Document Type: Editorial

References (16)

1. Knowledge document cellcept: CEL1035; fertility and pregnancy outcomes
2. Cellcept summary of product characteristics. European Medicines Agency. Available from: www.emea.europa.eu/humandocs/PDFs/EPAR/Cellcept/ H-082-Pl-en.pdf [Last accessed 3 April 2008]
3. El Sebaaly Z, Charpentier B, Snanoudj R. Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant 2007;22:2722
4. Perez-Aytes A, Ledo A, Boso V, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A 2008;146:1-7
5. Sifontis NM, Coscia LA, Constantinescu S, et al. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006;82:1698-702
6. Le Ray C, Coulomb A, Elefant E, et al. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 2004;103:1091-4
7. Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2005;69-83
8. Tjeertes IF, Bastiaans DE, van Ganzewinkel CJ, Zegers SH. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol 2007;27:62-4
9. Pergola PE, Kancharla A, Riley DJ. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation 2001;71:994-7
10. Wu A, Nashan B, Messner U, et al. Outcome of 22 successful pregnancies after liver transplantation. Clin Transplant 1998;12:454-64
11. Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 2000;70(12):1718-21
12. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92
13. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80
14. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28
15. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62
16. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121g-2131g